KORU Medical Systems, Inc.

Overview

"How the company got here" "KORU Medical Systems, Inc., originally founded as Repro Med Systems, Inc. in 1980, has evolved into a specialized medical device company. For decades, it has focused on developing and manufacturing infusion solutions designed for subcutaneous drug delivery. A significant turning point was the rebranding to KORU Medical Systems, Inc. in March 2022, signaling a renewed focus and potentially broader market ambitions. The company's core technology, the FREEDOM infusion system, has been a consistent element, with its first FDA clearance dating back to 1994. This long history has allowed KORU to build expertise in creating patient-centric solutions for chronic illness management." "What it actually does" "KORU Medical Systems designs, manufactures, and sells medical devices that help patients receive medications just under the skin, a method known as subcutaneous infusion. These devices, primarily the FREEDOM infusion systems, are used to deliver therapies for chronic conditions like primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's product line includes syringe drivers, specialized needle sets, and tubing, all engineered to provide a consistent and safe way for patients to administer their own treatments, often at home. KORU aims to give patients more control and flexibility in managing their health." "FREEDOM Infusion Systems" "KORU Medical Systems' primary business revolves around its FREEDOM infusion systems, which are mechanical devices designed for delivering medications under the skin. These systems include the FREEDOM60 and FreedomEdge syringe drivers, along with specialized needle sets and tubing. The FREEDOM60 is suited for larger volume infusions (over 30 mL), while the smaller FreedomEdge is designed for smaller doses (up to 30 mL). These devices are particularly important for patients with chronic illnesses who require regular medication, offering a more convenient and less invasive alternative to intravenous (IV) therapies. The company's revenue is largely derived from the sale of these infusion systems and related accessories." "Pharma Services and Clinical Trials" "Beyond its core product sales, KORU Medical Systems also operates a Pharma Services and Clinical Trials (PST) business. In this segment, the company provides its infusion products to biopharmaceutical companies for use during the drug development process, including feasibility studies and clinical trials. KORU can also customize its FREEDOM systems for specific drug categories, supporting these pharmaceutical partners as they bring new treatments to market. This business line represents a smaller but growing portion of KORU's overall revenue, offering opportunities to expand the use of its technology into new therapeutic areas." "What management is betting on now" "KORU Medical Systems is strategically focused on accelerating revenue growth through several key initiatives. A major priority is international expansion, particularly in Europe, to reach new markets and patient populations. Management is also working to diversify its product applications beyond immunoglobulin therapies, seeking clearances for its systems to be used with drugs in areas like oncology. Furthermore, the company is investing in its Pharma Services and Clinical Trials business to forge new collaborations with pharmaceutical companies. These efforts are aimed at increasing market share, expanding the addressable market for their infusion technology, and achieving sustained growth and profitability."